Home

Mars Bioimaging Ltd (MBI) was formed in 2007 to commercialise the ground-breaking MARS imaging system for its applications in medical diagnosis. The MARS imaging system is based on the new generation Medipix chip licensed out of CERN, Switzerland and technology developed by the University of Canterbury (UC) and partners. It has established itself as the world’s leading spectral (multi-energy ‘true colour') imaging technology. It is the first commercially available spectral, high definition computed tomography (CT) system and has already demonstrated exciting applications.

Spectral imaging, through its ability to accurately differentiate the atomic and density variation within body tissues, offers to revolutionise the field of computed tomography (CT) and provide a significant new technology platform for diagnostic imaging. The MARS imaging system promises images with new and improved diagnostic information, faster and at lower cost, with significantly lower radiation dose. This will significantly broaden both the value and use of CT as a diagnostic tool. MBI is the first company in the world to offer to the market a full spectral CT imaging system.